Three-week radiation course safe after mastectomy with reconstruction, RT CHARM trial shows
Start here
The RT CHARM trial (Alliance A221505), a randomized study in women with breast cancer undergoing mastectomy with breast reconstruction, compared a shorter 16-fraction radiation course delivered over 3-4 weeks against the standard 25-fraction schedule over 5-6 weeks. The trial found the shorter course noninferior to the standard schedule for reconstruction complications, meaning patients receiving reconstruction after mastectomy can be treated with a substantially briefer radiation regimen without compromising complication outcomes. The result addresses a setting where shorter courses had not previously been established as an option. For now, the trial stands as the key evidence supporting the abbreviated schedule; what remains open is how widely the approach is adopted in practice and whether additional outcomes from the trial inform patient selection.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- Medical XpressPickThree-week radiation course a safe option for breast cancer patients undergoing reconstruction, trial shows
The RT CHARM (Alliance A221505) randomized trial showed that for women undergoing reconstruction after mastectomy for breast cancer, a 16-fraction, 3-4 week radiation schedule was noninferior to a standard 25-fraction, 5-6 week regimen for reconstruction-complication safety.
Coverage and heat for this story
Reports so far 1·Heat now 6·Peak heat 10 (Oct 22 01:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.